Sign in

    Frank Brisebois

    Managing Director and Senior Biotechnology Research Analyst at Oppenheimer

    Francois Brisebois is a Managing Director and Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc., focusing on the biotechnology sector with coverage of companies such as Avadel Pharmaceuticals and Durect Corporation. He has issued more than 400 stock ratings, with a 31% success rate and an average return per rating of -7.5%, and his most profitable single rating yielded a 453% return. Brisebois has been with Oppenheimer since at least 2018, leveraging insights from experience and advanced education, including a degree from the University of Toronto. He holds professional credentials consistent with his senior analyst role and is recognized for his contributions to thematic research and sector-focused equity analysis.

    Frank Brisebois's questions to Processa Pharmaceuticals (PCSA) leadership

    Frank Brisebois's questions to Processa Pharmaceuticals (PCSA) leadership • Q1 2022

    Question

    Dan, on behalf of Frank Brisebois from Oppenheimer, asked if Processa is considering completing the PCS499 trial with fewer patients due to lower-than-expected prevalence and enrollment challenges, and if they plan to discuss this with the FDA.

    Answer

    CEO Dr. David Young confirmed they are considering a smaller sample size for the PCS499 trial. He noted the FDA has previously shown flexibility with rare disease trials facing enrollment difficulties. The viability of this approach would depend on achieving statistical significance, which would be aided by a very low response rate in the placebo group, a possibility they are hopeful for but cannot confirm until data is unblinded.

    Ask Fintool Equity Research AI